Wat is de prijs voor RegeneRx Biopharmaceuticals, Inc. (RGRX)

Het prijs van RegeneRx Biopharmaceuticals, Inc. (RGRX) is $0.0007

Wat is de marktkapitalisatie voor RegeneRx Biopharmaceuticals, Inc. (RGRX)

Marktkapitalisatie voorRegeneRx Biopharmaceuticals, Inc. (RGRX) is $1.05K

RegeneRx Biopharmaceuticals, Inc. (RGRX) Winst

RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000. Its operations are headquartered in Rockville, Maryland.

Jaar	Winst	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Winst

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Winst	Winstverschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	$3.01B	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Bedrijf

Winst

Winstverschil

Land